| Literature DB >> 33105842 |
Nicola Ellero1, Francesca Freccero1, Aliai Lanci1, Maria Morini1, Carolina Castagnetti1,2, Jole Mariella1.
Abstract
Oxytetracycline (OTC) administration has become a frequent practice in equine neonatology for the treatment of flexural limb deformity. The cause of this condition remains unclear but clinical studies revealed that following IV administration of OTC a relaxation of the metacarpophalangeal joint occurs in foals affected by flexural deformity. Studies concluded that OTC administration in neonatal foals did not adversely affect the kidneys. Other adverse effects of OTC have never been reported. This report presents two cases with different outcomes of 3-day-old foals which presented acute collapse and progressive depression after OTC administration. The clinical aspects, the increased activity of serum enzymes indicative of muscular damage, the presence of myoglobin in urine were clear diagnostic indicators of severe rhabdomyolysis, and the gross and histological findings confirmed a myopathy associated with renal damage in one case. Adverse effects on the musculoskeletal and urinary systems in healthy foals were first reported and were probably associated with multiple doses administered to foals less than 24-48 h old and/or at dosing intervals less than 24-48 h. The risk of development of rhabdomyolysis and nephrotoxicity in neonatal foals treated with OTC for flexural deformity from now on should be considered.Entities:
Keywords: acute renal failure; flexural deformity; neonatal foal; oxytetracycline; rhabdomyolysis
Year: 2020 PMID: 33105842 PMCID: PMC7711985 DOI: 10.3390/vetsci7040160
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Summary of alterations observed in the presented cases for serum biochemistry, arterial blood gas analysis, electrolyte concentrations and urinalysis.
| Case 1 | Case 2 | ||||||
|---|---|---|---|---|---|---|---|
| 24 Hours Post-Admission; 4 Hours After Single OTC Dose | 4 Days Post-Admission | 7 Days Post-Admission | Admission; 12 Hours After 3rd OTC Dose | 24 Hours Post-Admission | 48 Hours Post-Admission | ||
| parameter | ref. range | serum biochemistry | |||||
| CK (IU/L) | 52–143 [ | 62,300 | 4199 | 1238 | 1,000,000 | 999,999 | 102,000 |
| AST (IU/L) | 237–620 [ | 13,295 | 9894 | 3453 | 16,738 | 1 | 1 |
| LDH (IU/L) | 225–700 [ | 7136 | 1280 | 569 | 81,689 | 120,949 | 28,587 |
| creatinine (mg/dL) | 1.0–1.7 [ | 0.96 | 0.63 | NA | 1.18 | 1.14 | NA |
| urea (mg/dL) | 4–20 [ | 24.14 | 12.72 | NA | 32 | 59 | NA |
| phosphorus (mg/dL) | 5.4–9.4 [ | NA | NA | NA | 11.30 | 8.20 | NA |
| magnesium (mg/dL) | 1.12–1.85 [ | 2.23 | 2.10 | NA | 2.90 | 2.91 | NA |
| SAA (μg/dL) | NA | NA | NA | NA | 252 | 230 | NA |
| arterial blood gas analysis | |||||||
| pH | 7.36–7.39 [ | 7.28 | 7.36 | NA | 7.27 | 7.19 | 7.31 |
| paO2 (mmHg) | 84.7–89.1 [ | 61.6 | 84.5 | NA | 117 | 37.7 | 35.1 |
| paCO2 (mmHg) | 45.6–47.8 [ | 49.2 | 45.6 | NA | 35.7 | 41.7 | 48.9 |
| HCO3 (mmol/L) | 24.8–26.4 [ | 22.4 | 24.8 | NA | 16.5 | 14.6 | 21.9 |
| lactate (mmol/L) | 0.9–3.6 [ | 3.6 | 1.8 | NA | 15.1 | 15.3 | 17.4 |
| glucose (mmol/L) | 6.7–12.9 [ | 10.3 | 10.6 | NA | 1.1 | 14.1 | 10.3 |
| electrolyte concentrations | |||||||
| sodium (mmol/L) | 130–154 [ | 133 | 139 | NA | 130 | 140 | 142 |
| potassium (mmol/L) | 3.8–5.8 [ | 2.6 | 3.9 | NA | 4.3 | 3.2 | 3.1 |
| chloride (mmol/L) | 94–110 [ | 100 | 108 | NA | 94 | 89 | 97 |
| total calcium (mmol/L) | 2.8–3.4 [ | 1.14 | 1.18 | 2.8 | 0.86 | 0.58 | 0.76 |
| Urinalysis | |||||||
| USG | 1004–1008 [ | 1016 | 1, 12 | NA | 1012 | 1011 | 1012 |
| pH | 5.5–8.0 [ | 7 | 6.5 | NA | 5 | 5 | 5 |
| proteins (mg/dL) | neg. [ | 500 | neg. | NA | 100 | 100 | 30 |
| hemo/myoglobin (erythrocytes/μL) | neg. [ | 250 | 10 | NA | 250 | 250 | 250 |
| glucose (mg/dL) | neg. [ | 100 | neg. | NA | neg. | neg. | neg. |
| myoglobin casts | neg. [ | pos. | neg. | NA | neg. | pos. | pos. |
SAA: serum amyloid A; USG: urine specific gravity; NA: data not available. [12] Bauer, J.E.; Harvey, J.W.; Asquith, R.L.; McNulty, P.K.; Kivipelto, J.A.N. Clinical chemistry reference values of foals during the first year of life. Equine Vet. J. 1984, 16, 361–363. [13] Mariella, J.; Isani, G.; Andreani, G.; Freccero, F.; Carpenè, E.; Castagnetti, C. Total plasma magnesium in healthy and critically ill foals. Theriogenology. 2016, 85, 180–185. [14] Aguilera-Tejero, E.; Estepa, J.C.; Lopez, I.; Mayer-Valor, R.; Rodriguez, M. Arterial blood gases and acid-base balance in healthy young and aged horses. Equine Vet. J. 1998, 30, 352–354. [15] Castagnetti, C.; Pirrone, A.; Mariella, J.; Mari, G. Venous blood lactate evaluation in equine neonatal intensive care. Theriogenology. 2010, 73, 343–357. [16] Corley, K.T.T.; Stephen, J. Appendix. In The Equine Hospital Manual, 1st ed.; Corley, K.T.T., Stephen, J., Eds.; Blackwell: Oxford, UK, 2008; 654–689.
Figure 1Gluteus muscle, case 2. (A) Grossly, severe pale pink discoloration on cut section. (B) Histological cross sections of skeletal muscle. Hematoxylin & eosin (H&E). At low power, marked fragmentation, swelling and degeneration of skeletal muscle fibers and infiltration by small dark cells (identified at higher magnification as proliferating satellite cells) were observed. Scale bar, 500 μm; (C) At higher magnification, a cross section showing lysis and degeneration of myofibers (left), proliferating satellite cells and infiltrations of macrophages (right). Scale bar, 200 μm; (D) longitudinal section showing severe muscle fiber degeneration and multifocal mineralization. Scale bar, 100 μm.